- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2002–2023 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2023 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2020 · research · R01
Functional analysis of the Tip60 complex
Brendan D Price · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2023 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2029 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2023 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2024 · training · T32
Training in Oncology Population Sciences (TOPS)
Nancy L Keating · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2023 · training · T32
Training in Oncology Population Sciences (TOPS)
Nancy L Keating · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2029 · training · T32
Training in Oncology Population Sciences (TOPS)
Nancy L Keating · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2024 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2023 · training · T32
Training in Oncology Population Sciences (TOPS)
Nancy L Keating · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2023 · training · T32
Training in Oncology Population Sciences (TOPS)
Nancy L Keating · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2029 · research · R01
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2002–2029 · training · T32
Training in Oncology Population Sciences (TOPS)
Nancy L Keating · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2031 · cooperative agreement · UG1
BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2024 · cooperative agreement · UG1
A randomized phase 2 trial to compare standard-of-care steroids vs. steroids plus low-dose IL-2 vs. steroids plus low-dose IL-2 and rituximab for upfront treatment of chronic GVHD
Joseph H Antin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2001–2031 · cooperative agreement · UG1
BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium
Mahasweta Gooptu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2021 · research · R01
Regulation of the follicular T-cell response to autoimmunity
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2021 · research · R01
Regulation of the follicular T-cell response to autoimmunity
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2024 · research · R37
Cell Cycle Control of the Cytoskeleton
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2024 · research · R37
Cell Cycle Control of the Cytoskeleton
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2024 · research · R37
Cell Cycle Control of the Cytoskeleton
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2022 · research · R01
Regulation of the follicular T-cell response to autoimmunity
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2024 · research · R37
Cell Cycle Control of the Cytoskeleton
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2024 · research · R37
Cell Cycle Control of the Cytoskeleton
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2021 · research · R01
Regulation of the follicular T-cell response to autoimmunity
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2000–2021 · research · R01
Regulation of the follicular T-cell response to autoimmunity
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
1999–2020 · program · P01
Antigen Presentation and T cell Programming in Human Autoimmune Diseases
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
1997–2026 · research · R01
Polyploidy, Aneuploidy and Genome Stability
David S Pellman · Dana-Farber Cancer Institute · funded by National Institutes of Health
1997–2026 · program · P30
Dana-Farber/Harvard Cancer Center
Benjamin Levine Ebert · Dana-Farber Cancer Institute · funded by National Institutes of Health
1997–2021 · program · P30
Dana-Farber/Harvard Cancer Center
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
1997–2021 · program · P30
Dana-Farber/Harvard Cancer Center
Edward J Benz · Dana-Farber Cancer Institute · funded by National Institutes of Health
1997–2026 · program · P30
Dana-Farber/Harvard Cancer Center
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
1997–2021 · program · P30
Dana-Farber/Harvard Cancer Center
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
